معرفی
Dr. Andrew M. Lowy is a Professor of Surgery at the University of California San Diego School of Medicine, specializing in surgical oncology with a primary focus on pancreatic, liver, and gastrointestinal cancers. As a leading expert in pancreatic cancer treatment, he has pioneered the use of heated intraperitoneal chemotherapy (HIPEC) or 'chemo bath' for advanced abdominal cancers. Dr. Lowy serves on editorial boards of the Journal of Clinical Oncology and Annals of Surgical Oncology, and co-chairs the National Cancer Institute's Pancreatic Cancer Task Force.
His research centers on pancreatic carcinogenesis and therapy, with particular emphasis on the RON receptor tyrosine kinase and its role as a potential therapeutic target. His laboratory develops models for testing novel therapeutics, focusing on translational applications for pancreatic cancer treatment. His work spans molecular biology, cancer signaling pathways, and innovative therapeutic approaches including targeted therapies and immunotherapies.
Analysis of Dr. Lowy's recent publications reveals a strong emphasis on molecular mechanisms driving pancreatic cancer progression, with particular focus on tumor microenvironment interactions, metastasis mechanisms, and therapeutic resistance. His work increasingly incorporates advanced genomic and transcriptomic approaches while maintaining strong clinical relevance through participation in major cooperative group trials like SWOG.
Dr. Lowy has secured significant research funding as Principal Investigator on multiple NIH grants, including several R01 awards from the National Cancer Institute, demonstrating the importance and impact of his research program. His extensive involvement in clinical trials reflects his commitment to translating laboratory findings into improved patient care.
His laboratory and clinical team focus on advancing pancreatic cancer treatment through innovative surgical approaches, novel therapeutic targets, and biomarker development to guide personalized treatment strategies. The integration of basic science with clinical practice characterizes his comprehensive approach to improving outcomes for patients with gastrointestinal malignancies.
